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Abstract
The molecular basis for recognition by human P2Y1 receptors of the novel, competitive antagonist
2′-deoxy-N6-methyladenosine 3′,5′-bisphosphate (MRS 2179) was probed using site-directed
mutagenesis and molecular modeling. The potency of this antagonist was measured in mutant
receptors in which key residues in the transmembrane helical domains (TMs) 3, 5, 6, and 7 were
replaced by Ala or other amino acids. The capacity of MRS 2179 to block stimulation of
phospholipase C promoted by 2-methylthioadenosine 5′-diphosphate (2-MeSADP) was lost in
P2Y1 receptors having F226A, K280A, or Q307A mutations, indicating that these residues are
critical for the binding of the antagonist molecule. Mutation of the residues His132, Thr222, and
Tyr136 had an intermediate effect on the capacity of MRS 2179 to block the P2Y1 receptor. These
positions therefore appear to have a modulatory role in recognition of this antagonist. F131A,
H277A, T221A, R310K, or S317A mutant receptors exhibited an apparent affinity for MRS 2179
that was similar to that observed with the wild-type receptor. Thus, Phe131, Thr221, His277, and
Ser317 are not essential for antagonist recognition. A computer-generated model of the human
P2Y1 receptor was built and analyzed to help interpret these results. The model was derived
through primary sequence comparison, secondary structure prediction, and three-dimensional
homology building, using rhodopsin as a template, and was consistent with data obtained from
mutagenesis studies. We have introduced a “cross-docking” procedure to obtain energetically
refined 3D structures of the ligand–receptor complexes. Cross-docking simulates the
reorganization of the native receptor structure induced by a ligand. A putative nucleotide binding
site was localized and used to predict which residues are likely to be in proximity to agonists and
antagonists. According to our model TM6 and TM7 are close to the adenine ring, TM3 and TM6
are close to the ribose moiety, and TM3, TM6, and TM7 are near the triphosphate chain.
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The physiological actions of extracellular ATP1,2 have been comprehensively described and
include contractile regulation of the heart, as well as vascular and visceral smooth muscle,
excitatory and inhibitory effects on neurons of the central and peripheral nervous system,
and activation of neuroendocrine secretion. These effects are apparently mediated by a
family of G-protein-coupled receptors (P2Y) and ligand-gated ion channels (P2X).3 Seven
subtypes of P2X receptors and at least six distinct subtypes of P2Y receptors have been
cloned. P2Y1 receptors were the first in the series to be cloned4 and were shown to have the
seven transmembrane helical domain (TM) structure common for the superfamily of
rhodopsin-like G-protein-coupled receptors.5 Like other P2Y receptors, P2Y1 receptors
activate phospholipase C (PLC), which generates inositol phosphates and diacylglycerol
from phosphatidyl-inositol(4,5)bis-phosphate.6
Detailed structural studies of P2Y1 receptors have been limited by the lack of selective P2Y1
antagonists.7 Recently, we have synthesized a new, selective antagonist for P2Y1 receptors:
2′-deoxy-N6-methyladenosine 3′,5′-bisphosphate (MRS 2179),8 the chemical structure of
which is shown in Figure 1. A Ki of approximately 100 nM was determined for MRS 2179
acting as an antagonist at the PLC-coupled P2Y1 receptor in turkey erythrocyte
membranes.8 Due to its potency and structural similarity to agonists, we chose MRS 2179 as
a ligand to probe the P2Y1 receptor binding pocket.
Site-directed mutagenesis of human P2Y receptors was utilized for localizing agonist
recognition elements in two previous studies.9,10 Amino acid residues in TM3, TM5, TM6,
and TM7 were found to be involved in nucleotide binding to P2Y1 receptors.10 The potent
P2Y1 receptor agonist 2-methylthioadenosine 5′-triphosphate (2-MeSATP) had no activity
in cells expressing the R128A, R310A, and S314A mutant receptors (see Figure 2), and a
markedly reduced potency of 2-MeSATP was observed with the K280A and Q307A mutant
receptors. These and additional residues in the same transmembrane regions were selected to
probe the influence of individual side chains on the molecular recognition of the antagonist
MRS 2179 in the present study. Site-directed mutagenesis studies have been used in
combination with molecular modeling to predict the environment of agonist and antagonist
recognition pockets of the P2Y1 receptor.
Results
Functional Characterization of Mutant P2Y1 Receptors
Site-directed mutagenesis was carried out by standard methodology10–16 using
oligonucleotide primers. Wild-type and mutant HA-tagged human P2Y1 receptors were
expressed in Cos-7 cells and shown to be present in the plasma membrane by ELISA
measurements, as shown previously.10 The agonist 2-MeSADP, previously shown to be 5-
fold more potent than 2-MeSATP at this receptor,10 displayed an EC50 value for stimulation
of PLC17 in wild-type receptors of 1.94 nM (Table 1). Recently, we have synthesized 2′-
deoxy-N6-methyladenosine 3′,5′-bisphosphate, MRS 2179, as a selective and competitive
P2Y1 antagonist.8 The potency of this nucleotide antagonist was measured in the wild-type
(Figure 3A) and mutant (Figure 3A,B) human P2Y1 receptors. In wild-type receptors the
antagonist MRS 2179 at a concentration of 1 µM resulted in a 10-fold right shift of the
concentration–response curve of 2-MeSADP. This shift corresponded to a KB value for
MRS 2179 of 0.177 µM. Thus, the potency of MRS 2179 as a competitive antagonist at the
human P2Y1 receptor was similar to its reported potency at the turkey P2Y1 receptor.8
The effects of point mutations in the P2Y1 receptor on antagonist recognition were
examined and correlated with effects on agonist potency (Figure 3C). These mutant
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receptors can be divided into three groups based on the effects observed on antagonist
potency. For most mutations there is a linear relationship between EC50 for agonist vs KB
for antagonist. Thus, the effect of most mutations on agonist potency is proportional to the
effect on antagonist affinity. However, F131A, H277A, and R310K mutant receptors show
essentially the same antagonist affinity as wild-type receptors, while agonist affinity is
markedly reduced.
Residues Essential for Antagonist Recognition
Although 2-MeSADP is a potent activator of the F226A mutant receptor,10 1 µM MRS 2179
had no significant effect (p = 0.06) on the potency of 2-MeSADP in the stimulation of PLC
(<2-fold) in cells expressing this mutant receptor. Thus, amino acid residue Phe226 is
apparently more critical for recognition of the antagonist than for agonist. At K280A and
Q307A mutant receptors, 1 µM MRS 2179 was also ineffective as an antagonist of PLC
activation. For the K280A, Q307A, and Y136A mutant receptors, additional concentration–
response curves for 2-MeSADP were measured at a much higher concentration of MRS
2179 (50 µM). This concentration was selected based on the concentration effect
relationships for the antagonist at fixed concentrations of 2-MeSADP (Figure 3B) at these
three and at the S314T mutant receptors. Approximate IC50 values (µM) for antagonism of
PLC activation by MRS 2179 were 5 (S314T), 42 (Y136A), 30 (K280A), and 42 (Q307A).
In these experiments, the concentration of agonist was 3.3- (K280A), 7.7- (Q307A), 9.6-
(S314T), and 81- (Y136A) fold greater than the EC50 value at each mutant receptor in the
absence of MRS 2179. It was not feasible to measure the effect of MRS 2179 at the R128A,
R310A, and S314A mutant receptors, because the agonist did not fully activate these
receptors.10
Mutations Modulatory to Antagonist Recognition
At the H132A, Y136A, T222A, and S314T mutant receptors, MRS 2179 (1 µM) produced
an intermediate shift, i.e. a 2- to 3-fold reduction in agonist potency, of the concentration
response curve of 2-MeSADP. Thus, the His132, Tyr136, and Thr222 residues located in
TM3 and TM5 appear to have a modulatory role in recognition of this antagonist. Steric
requirements are present at Ser314, since the Thr substitution reduced the affinity of the
antagonist.
Mutations That Do Not Affect Antagonist Recognition
The shift in EC50 of 2-MeSADP promoted by 1 µM MRS 2179 at the F131A, T221A,
H277A, R310K, and S317A mutant receptors was nearly identical to that observed in wild-
type receptors (roughly an order of magnitude reduction in agonist potency). Thus, the
residues Phe131, Thr221, His277, and Ser317 are not essential for recognition of MRS
2179, and at amino acid residue Arg310, a side chain of similar positive charge (Lys) could
be substituted with no effect on antagonist potency.
Model of the Agonist Recognition Site
On the basis of the structure of rhodopsin which has sequence homology to GPCRs, we have
derived a human P2Y1 receptor model using the Sybyl program18 and other computational
methods,19–28 and docked ATP, the natural agonist, in the hypothetical binding site, in a
fashion that is consistent with all available pharmacological data.
Although a three-dimensional rhodopsin-like model of the chick P2Y1 receptor was
published previously,5 our description of ligand/P2Y1 receptor interactions has been
improved by including additional computational steps to explore the reorganization of the
native receptor structure induced by the ATP coordination (cross-docking). Figure 4 shows
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the 3D structural models of the human P2Y1 receptor before and after the application of
cross-docking with ATP. Several geometric parameters were unaffected by cross-docking:
the total length of the membrane-spanning region is about 40 Å; the interhelical distance
between the pairs of adjacent helical axes is about 10 Å, consistent with a common
interhelical contact distance;25 the interhelical angles, measured between the principal axes
of adjacent helices, are between −150° and 170° for antiparallel and between 10° and 25° for
the parallel helices (typical of a 3–4 type helix–helix contact associated with optimal
interactions between nearly parallel aligned helices).25 Each helix maintained almost the
same position and tilting found in the published rhodopsin 2D electron density map.26,27
TM5 in the ATP-bound cross-docked model has been rotated clockwise 60° about its
transmembrane axis with respect to the ligand-free receptor model. Consequently, the
position of Thr222 is shifted inside the helical bundle. This residue seems to be moderately
important in the coordination of the γ-phosphate of ATP, as demonstrated by site-directed
mutagenesis.10 Moreover, in the cross-docked model TM3, TM4, TM6, and TM7 were
rotated clockwise 5°, 15°, 10°, and 5°, respectively, about its transmembrane axis with
respect to the ligand-free receptor model. The energy of cross-docked ATP–receptor
complex structure is about 65 kcal/mol lower with respect to the original one.
As in the earlier modeling study of van Rhee et al.,5 ATP was present in the anti
conformation (χ, the torsion angle of the glycosidic bond C9–N9–C1′-O4′ was −3.8°),
consistent with the typical conformation based on crystallographic data for protein-bound
nucleotides. The ring puckering, defined by the dihedral angle C1′–C2′–C3′–C4′ was
18.8°, resulting in a 2′-exo, 3′-endo (3T2, North) conformation of the tetrahydrofuran ring.
Figure 5A represents the final helical bundle with ATP docked into the putative ligand
binding cavity. The putative orientation of bound nucleotide is slightly different from that
predicted in the previous modeling study,5 based on new specific interactions proposed as a
result of our site-directed mutagenesis studies.10 As shown in Figure 5A, the recognition of
ATP seems to occur in the upper region of the helical bundle. The adenine moiety of the
ATP molecule is most favorably oriented perpendicular to the plane of the lipid bilayer, with
the γ-phosphate of the triphosphate chain in proximity to the exofacial portion of TM5 and
the adenosine moiety near the midpoints of TM6 and TM7. From Figure 5A it is possible to
distinguish three different parts of the transmembrane domain responsible for ATP
recognition: TM6 and TM7 are close to the adenine ring; TM3 and TM6 are close to the
ribose moiety; and TM3, TM6, and TM7 are near the triphosphate chain.
There appear to be three favorable interactions between the adenine moiety of ATP and the
receptor. The side chain of Gln307(TM7) is within hydrogen-bonding distance of the N6
atom at 2.7 Å, and the side chain of Ser314(TM7) is positioned 2.0 Å from the N1 atom of
the purine ring. Arg310(TM7) is within ionic coupling range to both N7 and N9 atoms of the
adenine moiety. Three residues are tentatively implicated in the coordination of the ribose
structure. The side chain of His132(TM3) and O4′ are separated by 3.2 Å, His277-(TM6)
and O3′ are separated by 3.6 Å, and the Ser317-(TM7) is within hydrogen-bonding distance
of O2′ at 3.9 Å. The triphosphate side chain appears to be coordinated by Arg128 (TM3; 1.8
Å, O3γ and 1.7 Å, O2β), Tyr136 (TM3; 3.6 Å, O2α), Thr222 (TM5; 4.1 Å, O2γ), Lys280
(TM6; 1.7 Å, O3α), Arg310 (TM7; 2.6 Å, O3β).
The presence of three important basic residues (Arg128, Lys280, and Arg310) near the
extracellular environment seems to indicate that these amino acids are essential to the
coordination of the triphosphate moiety. Figure 6 shows the molecular surface of the P2Y1
receptor model color coded by electrostatic potential as calculated using GRASP25 with
Amber all-atoms atomic charges. The view is from the extracellular side directly into the
binding site, and the structure of ATP is highlighted. It is interesting to note the depth of the
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pocket and its positive electrostatic nature (blue color). The positive electrostatic potential of
the binding cavity overlaps very well with the negative potential generated by the negative
charges of the triphosphate moiety of ATP.
We also docked 2-MeSATP into the helical bundle. 2-MeSATP is 350-fold more potent than
ATP in activating P2Y1 receptors.2,30 We have tried to rationalize the higher potency of 2-
MeSATP vs ATP by comparing the geometry of the two structures docked within the
binding cavity. The methylthio derivative has almost the same position as the natural ligand,
although the coordination environment is slightly different. The presence of the bulky
methylthio substituent at the 2-position shifts the molecule further away from TM7
compared to ATP, as demonstrated by the increased distance of 3.4 Å between the side
chain of the Ser314-(TM7) and the N1 atom of the adenine ring. At the same time, more
favorable hydrogen-bonding interactions are possible between the side chains of
Gln307(TM7) and Ser314(TM7) with the N6 atom (distance 2.0 and 2.6 Å respectively) of
the 2-MeSATP. Also the interactions between Arg128 (TM3; 1.7 Å, O3γ and 1.6 Å, O2β)
and Thr222 (TM5; 3.1 Å, O2γ) with the triphosphate chain seem to be more geometrically
favorable with respect to those observed for ATP.
Model of the Antagonist Recognition Site
The possible modes of recognition of the 3′,5′-bisphosphate MRS 2179 in the P2Y1 binding
pocket was examined. There are two possible ways of overlapping ATP and MRS 2179: one
in which all the adenosine ring atoms are perfectly overlayed and another in which ATP α-
and γ-phosphorus atoms are overlayed to 3′- and 5′-phosphorus atoms of MRS 2179 (see
Figure 7). Ligand/receptor complexes with the two different arrangements of the MRS 2179
structure were constructed and optimized as previously described. The complex
corresponding to the adenosine overlay appeared more stable by approximately 40 kcal/mol.
Consistent with their structural similarity, the cross-docking procedure demonstrated that the
receptor architecture found for ATP recognition was energetically appropriate also for MRS
2179. Figure 5B represents the lowest energy docked complex of MRS 2179 in the proposed
ligand binding cavity. In the MRS 2179 cross-docked model, TM3, TM4, TM5, TM6, and
TM7 were rotated clockwise 10°, 15°, 55°, 5°, and 5°, respectively, about their
transmembrane axes with respect to the ligand-free receptor model. The energy of cross-
docked MRS 2179–receptor complex structure is about 50 kcal/mol lower with respect to
the original one. MRS 2179 was present in the anti conformation (χ, the torsion angle of the
glycosidic bond C9–N9–C1′-O4′ was −6.5°), consistent with the typical conformation
based on crystallographic data for protein-bound nucleotides. The ring puckering, defined by
the dihedral angle C1′–C2′–C3′–C4′ was 22.3°, resulting in a 2′-exo, 3′-endo (3T2, North)
conformation of the tetrahydrofuran ring.
In this model, the side chain of Gln307(TM7) is within hydrogen-bonding distance of the N6
atom at 1.7 Å, and the side chain of Ser314(TM7) is positioned at 1.9 Å from the N1 atom
and at 2.7 Å from the N6 of the purine ring. Another three amino acids are important for the
coordination of the phosphate groups in this antagonist: Arg128(TM3), Tyr136(TM3), and
Lys280(TM6). As shown in Figure 5B, Lys280 may interact directly with both 3′- and 5′-
phosphates (1.6 Å, O3′ and 1.6 Å, O5′), whereas Arg128(TM3) is within ionic coupling
range to both the O2 and O3 atoms of the 5′-phosphate. Tyr136 is also within hydrogen-
bonding distance of the 5′-phosphate at 3.8 Å. Thr222 is positioned at 4.8 Å from the 5′-
phosphate group of MRS 2179.
Discussion
Fundamental understanding of the molecular details of ligand/GPCR interactions remains
very rudimentary. How an agonist binds and transforms a resting GPCR into its active form
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and the microscopic basis of binding site blockade by an antagonist are generally still
unclear. In the absence of high-resolution structural knowledge of GPCRs, such questions
can be addressed only by building models, which are tested through pharmacological and
biochemical studies. Structural models can be used to describe the interatomic interactions
between a ligand and its receptor. We have extended our P2Y1 receptor model to describe
the possible manner in which the nucleotide coordination information is transmitted through
the receptor. We have sought to improve the description of ligand/receptor interactions by
introduction of a simple means to simulate the reorganization of the native receptor structure
accompanying ligand recognition. Our results illustrate that cross-docking can be used to
predict local structural changes induced by a ligand in a receptor binding site. As shown in
Figure 4, the presence of a bound nucleotide favors a simultaneous adjustment in the
orientation of TM3, TM5, TM6, and TM7. The most pronounced change upon docking of
ATP, i.e. rotation of TM5, is probably promoted by electrostatic interactions between the
phosphate groups and the basic amino acids of the binding cavity. Rotations and translations
of the TM domains are crucial factors in the ligand recognition process in different GPCRs,
as recently proposed by Gouldson et al.31 Consequently, our approach to docking is
designed to mimic the natural domain movement within the receptors.
It appears that the (tri)phosphate moiety of ATP and other nucleotide derivatives are the key
structure responsible for the binding and activation of the P2Y1 receptor. The negatively
charged triphosphate chain is likely coordinated to basic amino acids in the TMs, as
proposed previously,5,9,10 and may also be bound to the cationic side chains of the basic
amino acids of the extracellular loops possibly oriented toward the receptor cavity. Our
modeling study suggests that Arg128(TM3), Thr222(TM5), Lys280 (TM6), and
Arg310(TM7) are likely candidates for this counterion function. In particular, Arg128(TM3)
tentatively coordinates the α- and β-phosphate, Thr222(TM5) the γ-phosphate, Lys280-
(TM6) the α- and β-phosphate, and Arg310(TM7) the β-phosphate. Consistent with this
model, the R128A and R310A mutant receptors are not activated by agonists, and a
markedly reduced response is observed with the K280A mutant.10 Moreover, T221A and
T222A mutant receptors exhibit much larger reductions in triphosphate, rather than di- or
monophosphate potency.10 This result may be indicative of a greater role of these TM5
residues in γ-phosphate recognition. Thr222(TM5) and Lys280(TM6) in the human P2Y1
receptor are equivalent to Asn253 and Phe182 in the human A2A receptor, both of which
were implicated by Kim et al. in adenosine binding.29 Our model also reveals a high degree
of coordination of the β-phosphate and, probably, its crucial role in the binding process. This
observation is supported by the fact that ADP is more potent than ATP for activation of the
human P2Y1 receptor and that AMP is a very weak agonist for this receptor.10
Gln307(TM7) and Ser314(TM7) are positioned, in our model, in the vicinity of the N6
amine of the adenine moiety. We speculate that these two amino acids may be involved in
the recognition of the nucleotide base in the agonist structure. The important role of the exo-
cyclic NH6 of the adenine moiety, putatively through Gln307 as a hydrogen-bond acceptor,
has been demonstrated using a doubly alkylated N6 derivative of ATP, for which no agonist
activity was observed.5 Moreover, a markedly reduced response of 2-MeSADP was
observed for the Q307A mutant receptor compared with the wild-type receptor.10
A hydrogen bond between the N1 atom of the adenine ring and Ser314(TM7) is proposed in
our model. The S314A mutant receptor indeed exhibits low affinity for agonist ligands.10
Arg310(TM7) can also interact with both N7 and N9 atoms of the adenine ring. It is to be
noted that residues Gln307, Arg310, and Ser314 of the human P2Y1 receptor align with
Tyr271, Ile274, and His278 in the human A2A receptor sequence, which have been shown
by mutagenesis to be involved in ligand binding.29 Previous studies of A2A receptors have
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shown that TM7 is the critical region for the interaction of the adenine moiety in agonist
recognition.29
As previously reported, substitution at the 2-position of the adenine ring of the agonist
derivatives is tolerated and in some cases favored for P2Y receptor agonists.30 For example,
2-MeSADP is more potent than ADP, and 2-MeSATP is more potent than ATP. We suggest
that the presence of the bulky methylthio substituent at the 2-position shifts the position of
the agonist inside the binding cavity farther away from TM7, and this change enhances the
electrostatic interaction between the basic amino acids, Arg128 and Lys280, and the
negative charges of the phosphate side chain.
Tyr136(TM3) can also interact with the α-phosphate group of the ATP molecule. We
suggest that this interaction is a “secondary” interaction. In fact, alanine replacement of
Phe131(TM3), His132(TM3), Tyr136-(TM3), Phe226(TM5) or His277(TM6) resulted in
mutant receptors that exhibited 7–18-fold reductions in the potency of 2-MeSATP compared
with the wild-type receptor.10 These five residues in TM3, TM5, and TM6 are all close to
the ATP binding site and seem to play a modulatory role in ligand binding to the P2Y1
receptor.
From the present modeling study, the antagonist MRS 2179 can overlap the ATP structure
by superimposition of all adenine ring atoms (Figure 7). If this hypothesis is correct, all
amino acids important in the recognition of the adenine moiety of the ATP molecule should
also be important for MRS 2179 binding. Accordingly, the antagonist at 1 µM did not affect
the potency of 2-MeSADP in the Q307A and S314T mutant receptors, indicating that these
residues are important for the binding of the antagonists. This is additional evidence that the
TM7 region may be very important for the accommodation of the adenine moiety for both
agonists and antagonists.
We speculate that hydrogen bonding occurs between the N6 position of the adenine moiety
and the NH2 of Gln307. The apparent affinity of antagonists related to MRS 2179 is
dramatically dependent on the size of the N6 substituent.8 For example, the N6 propyl group
completely abolished antagonist properties, and double alkylation of the N6 amino group
resulted in a 300-fold decrease in apparent affinity of MRS 2179. It is possible to rationalize
these results from our model by proposing an unfavorable steric interaction between the
large N6 substituent and the side chain of Gln307.
Ser314(TM7) in the P2Y1 receptor–MRS 2179 complex can interact with both the N6 and
N1 atoms of the adenine moiety, but the N1 position seems to be preferred. This is in
accordance with the experimental evidence that the N1-methyl analogue of 2′-
deoxyadenosine 3′,5′-bisphosphate is a weak antagonist (13-fold loss of potency vs the
corresponding adenosine bisphosphate).8 The proximity between Ser314 and the adenine
moiety is also supported by the fact that the S314T mutation reduces the antagonist affinity.
Previously reported structure–activity relationships for adenosine bisphosphates at P2Y1
receptors8 suggest that either 2′- or 3′-deoxy modifications are completely tolerated in the
case of antagonists, while 2′- and 3′-deoxyATP are less potent (6.9- and 27-fold,
respectively) than ATP. For nucleotide antagonists, phosphate groups at either 2′- or 3′-
positions are nearly equivalent and also equally essential as a 5′-phosphate group for
antagonist properties. Our model suggests that two amino acids are important for the
coordination of the phosphate groups: Arg128(TM3) and Lys280(TM6). In particular,
Lys280 can interact directly with both 3′- and 5′-phosphates, and Arg128 is directly
involved in the coordination of the 5′-phosphates. The high flexibility of the side chain of
Lys280, and consequently the possibility that the amino group can also interact with the 2′-
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phosphate, may be the reason for the antagonist activity of both 2′,5′- and 3′,5′-
bisphosphates.
Thr222 seems to be too far from the 5′-phosphate group (4.8 Å) to participate in a direct,
strong hydrogen-bonding interaction with the ligand, but only one water molecule would be
sufficient to bridge the two groups. Phe226(TM5) is also located in proximity to the 5′-
phosphate group. Since a hydrophobic interaction occurring between the receptor and this
portion of the nucleotide is untenable, we speculate that this amino acid has an important
function in delineating the binding site cavity. It is likely that Arg128(TM3) and
Arg310(TM7) are very important for the binding of MRS 2179, just as they are for agonist.
However, the lack of responsiveness of these Ala mutant receptors to 2-Me-SADP made it
impossible to measure antagonist-binding properties.
Tyr136(TM3) seems to be modulatory for antagonist potency, just as for agonist potency. In
our model, Tyr136 can interact with the 5′-phosphate group of MRS 2179.
Alanine replacement of Phe131(TM3), His132(TM3), His277(TM6), or Ser317(TM7)
resulted in mutant receptors that exhibited apparent antagonist affinities similar to those
observed wisth the wild-type receptor. Thus, these residues are not essential for antagonist
recognition. Mutation of Ser317 is inconsequential to activation;10 however, the aromatic
residues Phe131, His132, and His277 are modulatory for agonist action.10 We speculate that
coordination of residues in TM3 and TM6 by the nucleotide may be related to
conformational changes leading to receptor activation. The differential effects on antagonist
affinity and agonist potency in F131A, H277A, and R310K mutant receptors (Figure 3C) do
not appear to be due to reduced intrinsic activity in these mutant receptors, since maximal
efficacy noted for three different agonists in these mutant receptors reached levels similar to
that type of wild-type receptors.10
Taken together, these results suggest that the adenosine and α-phosphate moieties are
critical for the binding of both agonists and antagonists to the P2Y1 receptor and that the
presence of β- and γ-phosphates are probably essential for the agonist activity of ATP. MRS
2179 and its related molecules are the only clearly competitive antagonists at the P2Y1
receptor. Other known antagonists such as PPADS, suramin, etc. likely have different
binding requirements at the receptor.8 Further studies may differentiate these requirements
and prove helpful for antagonist drug development.
Conclusions
Binding of the adenine nucleotide antagonist MRS 2179 to the human P2Y1 receptor
involves many of the same amino acid residues that are important for recognition of agonist
ATP derivatives: Lys280 and Gln307 are very important, and His132, Tyr136, and Thr222
are modulatory. Furthermore, residue S317 is not involved in binding of either agonists or
the antagonist MRS 2179. However, differences between agonist and antagonist recognition
were observed. In particular, Phe226 in TM5 is more important for the antagonist MRS
2179 than for agonists, and residues Phe131, Thr221, and His277 are less important for the
antagonist than for agonists. This has allowed us to construct rhodopsin-based molecular
models of the P2Y1–MRS 2179 and P2Y1–ATP complexes, allowing for minor adjustments
of the helical positions upon nucleotide binding. The binding modes for these two ligands
are very similar, especially in the adenine region; however a rotation of the antagonist
molecule allows direct interaction of both 5′- and 3′-monophosphate groups with the same
positively charged residues of the receptor that are putatively involved in recognition of the
5′-triphosphate moiety.
Moro et al. Page 8















Single amino acids of the human P2Y1 receptor cDNA (pcDNA3P2Y1) were mutated as
previously described.10 Briefly, the coding region of pCDNA3P2Y1 was subcloned into the
pCD-PS expression vector,12 yielding pCDP2Y1. All mutations were introduced into
pCDP2Y1 using standard polymerase chain reaction (PCR) techniques.10,13
Oligonucleotides (Bioserve Biotechnologies, Laurel, MD) were designed and used to
generate a PCR fragment, which was then used to replace the corresponding wild-type P2Y1
sequence. The accuracy of all PCR-derived sequences was confirmed by dideoxy
sequencing of the mutant plasmids.14 In addition to single amino acid replacement within
the TMs, the N-terminus of the receptor was appended with an epitope tag, consisting of a 9-
amino acid sequence derived from the influenza virus hemagglutinin (HA) protein (TAC
CCA TAC GAC GTG CCA GAC TAC GCG; peptide sequence: YPYDVPDYA) which was
inserted after the first Met residue.10,11 A HexaHis tag15 was also included at the C-terminus
immediately after the Leu residue resulting in a construct potentially suitable for affinity
chromatography using a chelated nickel column.
Mutant receptors were transiently expressed in COS-7 cells transfected approximately 24 h
after seeding with plasmid DNA (4 µg of DNA/dish) using the DEAE-dextran method.16
Cells were grown for an additional 48 h at 37 °C in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum.
Pharmacological and Immunological Methods
Inositol phosphate determination was used as the measure of activity of the ligands at the
mutant receptors. Stimulation by the agonist 2-methylthioadenosine 5′-diphosphate (2-Me-
SADP) (RBI, Natick, MA) and its antagonism by MRS 2179 (synthesized as the ammonium
salt, as described8) were measured in the wild-type and mutant receptors. The assay was
carried out according to the general approach of Harden et al.6 using [3H]-myo-inositol
(American Radiolabeled Chemicals, St. Louis, MO) in the presence of 10 mM LiCl for 30
min at 37 °C, 5% CO2. The [3H]inositol monophosphate fraction was isolated by anion
exchange chromatography17 and eluted with 4.5 mL of 0.1 M formic acid/0.2 M ammonium
formate. Pharmacological parameters were analyzed using the Kaleida-Graph program
(Abelbeck Software, version 3.01). Statistical analysis was performed using the unpaired t-
test (Prism, GraphPad, San Diego, CA).
Indirect cellular ELISA measurements were employed to demonstrate that the wild-type and
mutant receptors were expressed in the plasma membrane with the proper orientation of N-
terminus. Approximately 72 h after transfection, cells were fixed in 4% formaldehyde,
incubated with HA-specific monoclonal antibody (12CA5, Boehringer-Mannheim,
Indianapolis, IN), and then washed and incubated with a 1:2000 dilution of a peroxidase-
conjugated goat anti-mouse IgG antibody (Sigma, St. Louis, MO) for 1 h at 37 °C.10,29
Color reaction took place in the presence of hydrogen peroxide and o-phenylenediamine
(each 2.5 mM in 0.1 M phosphate–citrate buffer, pH 5.0) and was measured bichromatically
in the BioKinetics reader (EL 312, Bio Tek Instruments, Inc., Winooski, VT) at 490 and 630
nm (baseline).
Computational Methods
The human P2Y1 receptor model was built and optimized using Sybyl 6.318 and Macro-
model 5.019 modeling packages, respectively, based on the approach described by van Rhee
et al.5 All calculations were performed on a Silicon Graphics Indigo2 R8000 workstation.
Briefly, transmembrane domains were identified with the aid of Kyte–Doolittle
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hydrophobicity20 and Emini20 surface probability parameters. Transmembrane helices were
built from the sequences and minimized individually. The minimized helices were then
grouped together to form a helical bundle that matching the overall characteristics of the
electron density map of rhodopsin. The helical bundle was minimized using the Amber21
all-atoms force field until the rms value of the conjugate gradient (CG) was <0.1 kcal/mol
per Å. A fixed dielectric constant = 4.0 was used throughout these calculations.
A model of adenosine 5′-triphosphate (ATP) was constructed from the crystallographic
coordinates of ATP-phosphoglycerate kinase.22 2-MeSATP and MRS 2179 models were
constructed from ATP using the “Sketch Molecule” module of Sybyl. The ligands were then
fully minimized using AM123 of MOPAC24 and were rigidly docked into the helical bundle
using graphical manipulation coupled to continuous energy monitoring (Dock module of
Sybyl). When a final position was reached, consistent with a local energy minimum, the
complexes of receptor and ligand were subjected to an additional CG minimization run of
300 steps. Partial atomic charges for the ligands were imported from the MOPAC output
files.
We wanted to explore possible ligand-induced rearrangements of 7TM bundle by sampling
7TM conformations in the presence of the docked ligands. The docking process was
repeated for each model agonist– and antagonist–receptor complex after manually adjusting
the relative positions of TM3, TM4, TM5, TM6, and TM7 around the initial docked ligands
(our cross-docking procedure). Cross-docking was carried out using the Dock module of
Sybyl. Each helix was separated from the ligand–receptor complex structure, and its relative
position was changed until a new lower energy geometry was obtained. These adjustments
consisted of small translations and rotations of the principal axis of the helix with respect to
its original position. When a new final position was reached, consistent with the lowest local
energy minimum, the separated helix was merge again into the ligand–receptor complex.
The hydropathy profile for the new oriented helix was checked using Kyte–Doolittle
method.20 The new complex was subjected to an additional CG minimization run of 300
steps. This procedure was repeated for TM3, TM4, TM5, TM6, and TM7. The manual
adjustments were followed by 25 ps of molecular dynamics (MD module of Macromodel)
performed at a constant temperature of 300 K using time step of 0.001 ps and a dielectric
constant = 4.0. This procedure was followed by another sequence of CG energy
minimization to a gradient threshold of <0.1 kcal/mol per Å. Energy minimization of the
complexes was performed using the Tripos (SYBYL) and AMBER all-atom (MacroModel)
force field. The three-dimensional energy-minimized structures appear to be force-field-
independent, particularly in the binding region, as judged by backbone superposition with
SYBYL’s root-mean-square superposition procedure (rms = 0.014–0.22 Å).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ATP adenosine 5′-triphosphate
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DMEM Dulbecco’s modified Eagle’s medium
ELISA enzyme-linked immunosorbent assay
FBS fetal bovine serum
GPCR G-protein-coupled receptor
HA hemagglutinin
HBSS Hank’s balanced salt solution
2-Me-SADP 2-methylthioadenosine 5′-diphosphate
2-Me-SATP 2-methylthioadenosine 5′-triphosphate
MRS 2179 2′-deoxy-N6-methyladenosine 3, 5′-bisphosphate
PBS phosphate-buffered saline




TM transmembrane helical domain
Tris tris-(hydroxymethyl)aminomethane
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Chemical structures of ATP and MRS 2179 (charges not shown).
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Partial topology of the human P2Y1 receptor showing residues proposed to be involved in
recognition of the antagonist MRS 2179. Mutation sites in which replacement by alanine
significantly impedes the ability of MRS 2179 to block activation of the receptor are
highlighted. Gray shading indicates residues that are conserved between P2Y1 and P2Y2
receptors. Solid highlighted circles indicate a 1–3-fold change in the EC50 for 2-MeSADP in
the presence of 1 µM MRS2179; circles with thick outline, a 3–6-fold change; solid
nonhighlighted circles, a 6–12-fold change. Residues R128, R310, and S314 are highlighted;
however the effects of antagonist at these Ala mutant receptors could not be evaluated
experimentally due to lack of activation by agonist. The effects of non-Ala substitutions on
the potency of MRS 2179 are S314T, moderate reduction; R310K, identical to wild-type
receptors.
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Stimulation of phospholipase C by 2-MeSADP in human P2Y1 receptors. Transfected
COS-7 cells were incubated for 30 min at 37 °C (see the Experimental Procedures for
details). Data are presented as absolute accumulations of tritiated inositol phosphates above
basal levels in the absence of 2-MeSADP for representative experiments. EC50 values
(average of two to four independent experiments, each carried out in duplicate) are given in
Table 1. (A) Concentration–response curves for stimulation of PLC in the absence (open
symbols) or presence (closed symbols) of MRS 2179 in COS-7 cells transiently expressing
wild-type HA-tagged-hP2Y1 (○) or mutant hP2Y1 receptors (K280A, △; F131A, □)
Concentrations of MRS 2179 used were K280A, 50 µM; wild-type and F131A, 1 µM. (B)
Moro et al. Page 15













Concentration–response curves for antagonism by MRS 2179 of agonist-induced stimulation
of PLC in four mutant receptors. Concentrations of 2-MeSADP used were: K280A, 5 µM
(○); Q307A, 2.5 µM (●); S314T, 100 nM (◆); Y136A, 1 µM (◇). (C) Correlation of
agonist (EC50, nM) vs antagonist (KB, µM) potencies at mutant hP2Y1 receptors (mutations
having little or no effect on antagonist affinity, △; mutations having an intemediate effect on
antagonist affinity; □, mutations having the largest effect on antagonist affinity, ●). An
estimated KB value for F226A of 2.6 µM has been used.
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Stereoview of human P2Y1 receptor transmembrane helical bundle model viewed along the
helical axes from the extracellular end (A, top) and perpendicular to the helical axes (B,
bottom), before (left) and after (right) the “cross-docking” procedure for the P2Y1–ATP
complex (see the Experimental Procedures for details). The docked ATP molecule is not
shown. Side chains of some amino acids important for ligand recognition are highlighted.
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(A, Top) Side view of the P2Y1–ATP complex model. The side chains of the important
residues in proximity to the docked ATP molecule are highlighted and labeled. Residues in
proximity (≤5 Å) to the docked ATP molecule: adenine Q307, R310, S314; ribose H132,
H277, S317; triphosphate R128, Y136, T222, K280, R310. (B, Bottom) Side view of P2Y1–
MRS 2179 complex model. The side chains of the important residues in proximity to the
docked MRS 2179 molecule are highlighted and labeled. Residues in proximity (≤5 Å) to
the docked MRS2179 molecule: adenine Q307, R310, S314; ribose H132, H277;
bisphosphate R128, Y136, K280, R310 (R128 and K280 present different conformations
with respect to the ATP binding model).
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Surface potential of P2Y1–ATP complex model, displayed with GRASP.25 The molecular
surface is color coded by electrostatic potential. Potentials less than −20 kT are red, those
greater than 20 kT are blue, and neutral potentials (0 kT) are white. The ATP binding site is
clearly distinguishable as a region of intense positive potential.
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Possible superpositions of ATP and MRS 2179. (A) Superposition of all adenosine ring
atoms or (B) superposition of ATP α- and γ-phosphate atoms with 3′- and 5′-phosphate of
MRS 2179.
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